^
    CANCER:

    Chronic Myeloid Leukemia





    Show legend
    Group by Gene:
    Include preclinical:

    nilotinib
    olverembatinib
    		0
    Bcr-abl tyrosine kinase inhibitor
    PF-114
    TGRX-678
    SCO - 088
    KF-1601
    1
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor
    bosutinib
    2
    Multi-tyrosine kinase inhibitor
    ponatinib
    midostaurin
    3
    Alkylating agent
    busulfan
    4
    VEGFR inhibitor
    axitinib
    5
    MYC inhibitor
    GT19077
    6
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    7
    BTK inhibitor
    acalabrutinib
    8
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    dasatinib + nilotinib
    9
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    imatinib + nilotinib
    10
    MCL1 inhibitor, Protein synthesis inhibitor, MYC inhibitor, Apoptosis stimulant, G1-S-specific cyclin-D1 inhibitor
    omacetaxine mepesuccinate
    11
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    12
    STAMP inhibitor, Bcr-abl tyrosine kinase inhibitor
    asciminib
    nilotinib + asciminib
    13
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    14
    Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
    venetoclax + ponatinib
    15
    VEGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + axitinib
    16
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    17
    EGFR inhibitor
    EGFR inhibitor
    18
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, Bcl2 inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    venetoclax + dasatinib
    19
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, Bcl2 inhibitor
    venetoclax + bosutinib
    20
    Bcr-abl tyrosine kinase inhibitor, Bcl2 inhibitor
    venetoclax + nilotinib
    21
    STAMP inhibitor, PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib + asciminib
    22
    Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    flumatinib
    23
    STAMP inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + asciminib
    24
    Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor, Bcl2 inhibitor
    venetoclax + flumatinib
    25
    CD19 inhibitor, CD3 agonist, Multi-tyrosine kinase inhibitor
    ponatinib + blinatumomab
    26
    IDH1 inhibitor, Bcl2 inhibitor
    venetoclax + ivosidenib
    27
    T-lymphocyte cell therapy
    T-lymphocyte cell therapy
    28
    HDAC inhibitor, PI3K inhibitor
    CUDC-907
    29
    XPO1 inhibitor, Bcl2 inhibitor
    venetoclax + selinexor
    30
    Bcl2 inhibitor
    venetoclax
    31
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + imatinib
    dasatinib + imatinib + nilotinib
    32
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    33
    Nicotinamide phosphoribosyltransferase inhibitor, Multi-tyrosine kinase inhibitor
    ponatinib + GMX1778
    34
    STAT3 inhibitor, Insulin receptor substrate protein inhibitor
    NT-157
    35
    Bcr-abl tyrosine kinase inhibitor, Multi-tyrosine kinase inhibitor
    ponatinib + TGRX-678
    36
    HDAC inhibitor, PI3K inhibitor, Multi-tyrosine kinase inhibitor
    ponatinib + CUDC-907
    37
    VEGFR inhibitor, STAMP inhibitor, Bcr-abl tyrosine kinase inhibitor
    axitinib + asciminib
    38
    ATR inhibitor
    VE-821
    No biomarker
    BCR-ABL1 fusion
    BCR-ABL1 T315I
    BCR-ABL1 E459K
    BCR-ABL1 L248V
    BCR-ABL1 Q252H
    BCR-ABL1 E355G
    BCR-ABL1 L387M
    BCR-ABL1 D276G
    BCR-ABL1 E279K
    BCR-ABL1 H396R
    BCR-ABL1 F486S
    BCR-ABL1 M244V
    BCR-ABL1 A397P
    BCR-ABL1 I432T
    BCR-ABL1 S417Y
    BCR-ABL1 C475V
    BCR-ABL1 Y253F
    BCR-ABL1 L387F
    BCR-ABL1 Q300R
    BCR-ABL1 E355G + BCR-ABL1 Q252R
    BCR-ABL1 H396P
    BCR exon 13-ABL1 exon 3 fusion
    BCR-ABL1 M388L + BCR-ABL1 M244V
    BCR-ABL1 M388L
    BCR-ABL1 mutation
    BCR-ABL1 E98G
    BCR-ABL1 E450Q
    BCR-ABL1 L364I
    BCR-ABL1 E450G
    BCR-ABL1 D444G
    BCR-ABL1 D363G
    BCR-ABL1 L323P
    BCR-ABL1 I403V
    BCR-ABL1 I403T
    BCR-ABL1 V289I
    BCR-ABL1 G250E + BCR-ABL1 F317L
    BCR-ABL1 V299L
    BCR-ABL1 E255V
    BCR-ABL1 M351T
    BCR-ABL1 F359I
    BCR-ABL1 F359V
    BCR-ABL1 Y253H
    BCR-ABL1 E255K
    BCR-ABL1 F359C
    BCR-ABL1 N336S
    BCR-ABL1 E453A
    BCR-ABL1 V379I
    BCR-ABL1 F317L
    BCR-ABL1 G250E
    BCR-ABL1 A337T
    BCR-ABL1 P465S
    BCR-ABL1 Q255K
    BCR-ABL1 S417T
    BCR-ABL1 L384M
    BCR-ABL1 F317C
    BCR-ABL1 F317V
    BCR-ABL1 F317I
    BCR-ABL1 T315A
    BCR-ABL1 G398R
    BCR-ABL1 Y253H + BCR-ABL1 T315I
    BCR-ABL1 Q252R
    BCR-ABL1 F3llL
    BCR-ABL1 E292V
    BCR-ABL1 F311I
    BCR-ABL1 F311V
    BCR-ABL1 L248R
    RAI1 Q280fs
    CELF2 -93_-93insGAGAGA
    KIT V560G
    CELF2 -93_-93delGAGA
    RAI1 Q279fs
    KIT D816V
    TP53 -181_-179delAAA
    ABL1 T315I
    KCNJ12 -52C>T
    MYO16 *170_*179delTTGTGTGTGT
    ANO5 *113delT
    CACNA1B N167K
    JAK2 rearrangement
    PCM1-JAK2 fusion
    KRAS G12A
    miR-21 underexpression
    miR-451 overexpression
    NR1I2 rs3814055
    ABCB1 3435C>T
    miR-199a overexpression
    BCR-ABL1 fusion + SET underexpression
    FLT3 D835
    ASXL1 mutation
    IDH1 mutation
    BRAF V600E
    TTN 10361-5delT
    CSF3R T618I
    PTPN22 2135-4delT
    BCR exon 1-PDGFRA exon 13 fusion
    PDLIM4 -62_-60TGC
    FLT3 mutation
    ABL1 F317L
    ASXL1 deletion
    ABL1 T315I + ABL1 M351T + ABL1 L387M
    ABL1 F359V
    ABL1 L387M
    ASXL1 G646Wfs*12
    ABL1 E255K
    ABL1 M351T
    ABL1 G250E
    FLT3 G697R
    ABL1 D276G
    ABL1 Y253H
    Chr t(9;11)
    miR-146a expression
    Chr t(4;9;22)(q21;q34;q11)
    Chr t(1;16)(q12;q11.2)
    Chr t(4;9;22)(q21;q34;q11.2)
    ABCC2 3972C>T
    PRKCH overexpression
    RUNX1 mutation
    STAT5A mutation
    PHF6 mutation
    CIP2A elevation
    MEF2D-CSF1R fusion
    IKZF1 mutation
    SF3B1 mutation
    CD19 expression
    PTEN underexpression
    MYC-IGH fusion
    CD34 positive
    SF3B1 K666N
    DNMT3A deletion
    RXRA overexpression
    KDM4D mutation